Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.56 |
| ▸ | MTOR | P42345 | 9/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.54 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.53 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12885245 | 0.86 | PIK3CA (0.52) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL1192173 | 0.86 | PIK3CA (0.53) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL1311249 | 0.82 | MTOR (0.59) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL1192763 | 0.81 | PIK3CA (0.38) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL4435422 | 0.80 | MTOR (0.67) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL1192769 | 0.79 | PIK3CA (0.64) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL4446926 | 0.78 | MTOR (0.67) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL1192331 | 0.78 | PIK3CA (0.61) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL1311868 | 0.78 | PIK3CA (0.73) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL1191889 | 0.75 | MTOR (0.73) | PIK3CAMTORPIK3CBPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207781-B1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2012-11-28 | — | — | EP | claimed |
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-05-12 | — | — | US | claimed |
| EP-2207781-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2010-07-21 | — | — | EP | claimed |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-05-07 | — | — | US | claimed |
| WO-2009042607-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-04-02 | — | — | WO | claimed |
| EP-2207781-B1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2207781-B1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2012-11-28 | — | — | EP | disclosed |
| US-8158626-B2 | Thiazolopyrimidine PI3K inhibitor compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-17 | — | — | US | disclosed |
| US-8158626-B2 | Thiazolopyrimidine PI3K inhibitor compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-17 | — | — | US | disclosed |
| US-8158626-B2 | Thiazolopyrimidine PI3K inhibitor compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-17 | — | — | US | disclosed |
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7893059-B2 | Thiazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893059-B2 | Thiazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| WO-2009042607-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885MTOR 13/4885PIK3CB 3/4885 |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PI4KB, PI4KA | PIK3CA 1/4885MTOR 59/4885PIK3CB 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.